Mitigating conduction disturbances in sutureless aortic valve surgery: A standardized anti-oversizing strategy in a large single-center program Authors: Miguel Barbeito González, Gabriel González Barbeito, María García Vieites, Carlos Velasco García de Sierra, Víctor Xesus Mosquera Rodríguez, Francisco Estévez Cid, José Martínez Comendador, José J. Cuenca Castillo Published: 2026 ABSTRACT ObjectivesThe study objectives were to characterize conduction outcomes and perioperative results in a large, consecutive, single-center program of sutureless self-expanding aortic bioprosthesis implantation and to assess the temporal impact of a standardized, nonoversizing, higher-release implant strategy on permanent pacemaker implantation.MethodsWe conducted a retrospective cohort study including all sutureless aortic valve procedures performed between October 2013 and March 2025 (n = 1742). Outcomes assessed were permanent pacemaker implantation for complete atrioventricular block, stroke, reexploration for bleeding, renal replacement therapy, infection, and in-hospital mortality. Prespecified subgroup analyses were performed for isolated aortic valve surgery and by surgical approach (full sternotomy vs ministernotomy). Temporal trends were examined across the program's learning curve, with 2017 marking the adoption of a standardized conservative depth, no oversizing implantation strategy. Body size index–prosthesis size interactions were explored using heat-map analyses.ResultsOverall permanent pacemaker implantation occurred in 96 of 1742 patients (5.5%). Rates of stroke, reexploration for bleeding, renal replacement therapy, and in-hospital mortality were 1.7%, 4.7%, 1.8%, and 3.4%, respectively. In isolated surgery (n = 1281), ministernotomy was associated with lower stroke (0.95% vs 3.30%; P = .003), lower renal replacement therapy (0.63% vs 3.00%; P = .001), and lower in-hospital mortality (1.69% vs 6.31%; P < .001) compared with full sternotomy, and permanent pacemaker implantation rates were similar (5.27% vs 5.11%; P = .908). Cumulative permanent pacemaker implantation incidence decreased from early values of approximately 12 to 14% to 5 to 6% after 2017, paralleling adoption of the standardized implantation strategy. Heat-map analyses demonstrated pre-2017 oversizing “hot spots” that largely resolved after standardization.ConclusionsIn a large real-world sutureless aortic valve program, standardization of sizing and implant depth was associated with sustained reduction in permanent pacemaker implantation without compromising clinical outcomes. Avoidance of oversizing appears central to optimizing conduction results. Standardized sizing strategy mitigates oversizing and reduces PPI. Central MessageStandardized avoidance of prosthesis oversizing and higher-release implantation are associated with reduced PPI in sutureless AVR without compromising clinical outcomes. PerspectiveConduction disturbances after sutureless AVR are not an unavoidable trade-off. Large program experience shows that standardized sizing and implant depth may durably reduce PPI while maintaining the procedural and clinical advantages of sutureless and minimally invasive aortic valve surgery. Standardized sizing strategy mitigates oversizing and reduces PPI. Central Message Standardized avoidance of prosthesis oversizing and higher-release implantation are associated with reduced PPI in sutureless AVR without compromising clinical outcomes. Perspective Conduction disturbances after sutureless AVR are not an unavoidable trade-off. Large program experience shows that standardized sizing and implant depth may durably reduce PPI while maintaining the procedural and clinical advantages of sutureless and minimally invasive aortic valve surgery. Sutureless and rapid-deployment aortic valve prostheses have been increasingly adopted as an alternative to conventional surgical aortic valve replacement (AVR), particularly in elderly patients and in minimally invasive approaches.1,2 By eliminating or reducing the need for annular suturing, these technologies offer potential advantages in procedural efficiency, reduced cardiopulmonary bypass and aortic crossclamp times, and facilitation of minimally invasive access without compromising early hemodynamic performance.3, 4, 5, 6 Despite these advantages, conduction disturbances requiring permanent pacemaker implantation (PPI) remain a relevant concern after implantation of self-expanding sutureless aortic bioprostheses.7,8 This issue has gained particular importance in the contemporary valve landscape, where transcatheter aortic valve replacement (TAVR) has expanded rapidly toward younger and lower-risk patients, especially in the United States.9, 10, 11 In this setting, the relatively high incidence of conduction disturbances after TAVR has emerged as a recognized limitation, raising concerns about long-term pacing dependency in patients with extended life expectancy.12,13 Against this background, it is critical that surgical alternatives (particularly sutureless AVR) do not replicate the same Achilles’ heel with respect to atrioventricular conduction injury. Reported PPI rates after sutureless AVR vary widely across published series, reflecting differences in patient selection, prosthesis design, implantation technique, and institutional experience.7,14,15 Of note, PPI has been associated with increased morbidity, prolonged hospitalization, and potential adverse effects on long-term outcomes, underscoring the clinical relevance of strategies aimed at mitigating this complication.16,17 Several mechanisms have been proposed to explain conduction disturbances after implantation of self-expanding sutureless prostheses, including mechanical compression of the conduction system related to prosthesis radial force, implant depth, and prosthesis–annulus interaction.18,19 Among these factors, prosthesis oversizing has emerged as a potentially modifiable determinant of atrioventricular conduction injury. However, the extent to which systematic avoidance of oversizing and standardization of implantation depth can durably influence conduction outcomes in large, real-world programs remains incompletely defined. Most available reports describe aggregated outcomes without detailed evaluation of temporal trends or technique evolution, limiting the ability to distinguish learning-curve effects from the impact of deliberate procedural modifications.20, 21, 22 Furthermore, data exploring the interaction among patient body size, prosthesis size selection, and conduction outcomes are scarce, particularly in long-term, high-volume single-center experience. The present study analyzes a large, consecutive, single-center experience with a sutureless self-expanding aortic bioprosthesis over more than a decade. By leveraging detailed procedural data and longitudinal follow-up, we sought to characterize conduction outcomes and perioperative results, and to evaluate the temporal effect of a standardized implantation strategy focused on avoidance of prosthesis oversizing and conservative implant depth. In addition, we explored the relationship between body size indices and prosthesis sizing using heat-map analyses, with the aim of providing practical, reproducible insights applicable to contemporary sutureless aortic valve programs. Material and Methods Study Design and Patient Population This study is a retrospective observational cohort analysis including all consecutive patients who underwent sutureless AVR with a self-expanding bioprosthesis at a single tertiary referral center between October 2013 and March 2025. The study population comprises the complete institutional experience with this technology during the study period, without case selection or exclusion based on operative risk, surgical approach, or associated procedures. All adult patients undergoing sutureless AVR as an isolated procedure or in combination with other cardiac surgical interventions were eligible for inclusion. Baseline demographic characteristics, clinical comorbidities, operative details, and postoperative outcomes were prospectively recorded in an institutional database and retrospectively analyzed for the purposes of the present study. Patients undergoing redo cardiac surgery, urgent or emergency procedures, and concomitant cardiac operations were included to reflect real-world clinical practice. Combined procedures included coronary, mitral, and aortic interventions; no concomitant rhythm correction procedures (eg, Maze or surgical ablation for atrial fibrillation) were performed in this cohort. Surgical approach (full sternotomy or ministernotomy), type of procedure (isolated vs combined surgery), and prosthesis size selection were determined at the discretion of the operating surgeon according to institutional standards and evolving program experience. The study cohort was stratified according to the temporal evolution of the institutional implant strategy. Based on predefined changes in surgical technique and sizing philosophy, cases were analyzed across different time periods, with the year 2017 marking the implementation of a standardized implantation strategy focused on avoidance of prosthesis oversizing and conservative implant depth. Surgical Technique and Implant Strategy All procedures were performed using a self-expanding sutureless aortic bioprosthesis (Perceval; LivaNova). Surgical access was selected according to institutional strategy, patient characteristics, and procedural complexity. In isolated AVR, the preferred and default surgical approach was upper ministernotomy in a J configuration, whenever adequate anatomic exposure was anticipated and no contraindications were present. Full median sternotomy was reserved for patients undergoing concomitant cardiac procedures or redo surgery, or when minimally invasive access was not feasible. After establishment of cardiopulmonary bypass and aortotomy, the native aortic valve was excised and the annulus carefully decalcified following standard surgical principles. Prosthesis sizing was primarily based on direct intraoperative annular assessment using the manufacturer's dedicated sizing system. Preoperative imaging was used to evaluate anatomy and procedural feasibility; however, MDCT-derived annular measurements were not systematically used as the primary sizing method throughout the study period. Initial Implantation Technique (Pre-2017) During the early phase of the program, valve implantation followed the standard Perceval sutureless AVR technique, including sizing strategy, guiding suture placement, and deployment sequence, as previously described in detail in the operative literature.23 Guiding sutures were typically positioned 2 to 3 mm below the annular plane, and prosthesis sizing relied on allowing passage of the transparent obturator (corresponding to the minimal prosthesis diameter) through the annulus, while the white obturator (corresponding to the maximal external prosthesis diameter) was not permitted to cross the annular plane under standard conditions. Balloon postdilatation was routinely performed after valve deployment, with inflation times of approximately 30 seconds, in accordance with the original implantation protocol. Standardized Modified Implantation Strategy (From 2017 Onward) From 2017 onward, a standardized modified implantation strategy was progressively implemented across the program, based on accumulated institutional experience (reflecting iterative technical refinement and internal outcome analysis) and emerging evidence highlighting the role of prosthesis oversizing and implant depth in conduction disturbances. Guiding sutures were systematically placed at a more superficial level within the nadir of the aortic sinuses, closer to the annular plane, to limit downward traction of the prosthesis toward the left ventricular outflow tract. The valve was introduced across the annulus in a fully collapsed configuration without tension on the guiding sutures, allowing controlled advancement and subsequent gentle retrograde traction to seat the prosthesis at the annular level before final release. This approach was intended to facilitate accurate positioning and minimize prosthesis descent into the ventricular outflow tract. A central component of the modified strategy was adoption of a conservative sizing philosophy to avoid prosthesis oversizing. Recognizing the self-expanding properties of the nitinol frame and the fact that annular assessment is performed under cardioplegic diastolic conditions, prosthesis selection was standardized such that the white obturator was required to gently contact the annulus and to pass only with light forward pressure directed toward the left ventricular outflow tract. If passage occurred under this controlled maneuver, the corresponding prosthesis size was selected. Balloon postdilatation was no longer routinely performed, and, when required, inflation time was deliberately limited to 5 seconds or less. The modified implantation strategy was applied consistently across surgical approaches and adopted by all surgeons participating in the program. The differences between the initial and modified implantation strategies are summarized in Figure 1.Figure 1Schematic representation of the evolution from the classic to the modified implantation strategy in sutureless AVR. Schematic representation of the evolution from the classic to the modified implantation strategy in sutureless AVR. Outcomes and Definitions The primary outcome of the study was the need for PPI during the index hospitalization after sutureless AVR. PPI was defined as implantation of a permanent pacemaker due to complete atrioventricular block or advanced atrioventricular conduction disturbance considered persistent and nonreversible by the treating team. The study specifically focused on high-grade atrioventricular conduction disorders leading to permanent pacing. Other postoperative electrocardiographic changes not resulting in PPI were not considered primary outcomes and were not analyzed as independent end points. Secondary outcomes included early clinical outcomes and perioperative efficiency metrics. Procedural variables comprised cardiopulmonary bypass time and aortic crossclamp time. Postoperative variables included length of intensive care unit stay and total postoperative hospital stay. Early clinical events were recorded during the index hospitalization and included in-hospital mortality and major postoperative complications according to institutional definitions. To explore the relationship between implantation strategy and conduction outcomes, prosthesis sizing relative to patient body size was analyzed as a technical explanatory variable. Body size indices were combined with implanted prosthesis size to evaluate patterns of relative prosthesis sizing and potential oversizing. These interactions were subsequently visualized using heat-map analyses. Patients were analyzed according to prespecified subgroups, including isolated versus combined procedures, surgical approach (upper ministernotomy vs full sternotomy), and temporal period reflecting implantation strategy (pre-2017 vs from 2017 onward). Statistical Analysis Continuous variables are presented as mean ± SD or median with interquartile range, according to data distribution. Categorical variables are expressed as absolute numbers and percentages. Normality of continuous variables was assessed using visual inspection of distributions and standard normality tests, as appropriate. The European System for Cardiac Operative Risk Evaluation II did not follow a normal distribution (Shapiro–Wilk test P < .001) and therefore was considered primarily as a descriptive variable. Comparisons between groups were performed using the Student t test or Mann–Whitney U test for continuous variables and the chi-square test or Fisher exact test for categorical variables, depending on data characteristics and expected cell counts. Temporal comparisons across predefined implantation periods were conducted using the same univariable statistical approach. The association between the implantation strategy and the primary outcome (PPI) was explored using univariable logistic regression and, when appropriate, multivariable logistic regression models based on clinical plausibility and statistical criteria. To explore the relationship between prosthesis sizing relative to patient body size and the primary outcome, body size indices were combined with implanted prosthesis size to construct 2-dimensional interaction matrices and were visualized using heat-map analyses, generated separately by implantation period. The height-to-body surface area (height/BSA) index was used as an anatomic scaling parameter to reflect the proportional relationship between patient size and aortic root dimensions, rather than as a marker of body composition. For heat-map representation, the height/BSA index was grouped into fixed-width intervals to improve visualization of distributional patterns across the cohort. Patients with a preoperative permanent pacemaker were included for baseline descriptive purposes but were excluded from analyses evaluating predictors of postoperative PPI. Missing data were not imputed and were analyzed as missing, with analyses performed using all available observations for each variable and outcome. All statistical analyses were performed using Stata version 18 (StataCorp LLC). Results Study Population and Baseline Characteristics A total of 1742 patients undergoing AVR with a sutureless Perceval prosthesis were included in the study. Baseline demographic, anthropometric, and clinical characteristics of the study population are summarized in Table 1.Table 1Baseline demographic and clinical characteristicsVariableValueAge, y73.2 ± 6.8Weight, kg75.1 ± 13.0Height, cm160.8 ± 9.1Body mass index, kg/m229.3 ± 11.1BSA, m21.79 ± 0.18Height/BSA index, cm/m290.5 ± 6.3euroSCORE II, %3.35 ± 4.5Male sex55.2% (962)Hypertension75.3% (1311)Diabetes mellitus Diet-controlled0.1% (2) Oral treatment4.8% (83) Insulin-treated2.0% (35)Dyslipidemia69.7% (1214)Atrial fibrillation10.7% (187)Chronic obstructive pulmonary disease11.4% (198)Severe peripheral arterial disease5.3% (92)Preoperative sinus rhythm58.7% (1023)NYHA functional class Class I0.75% (13) Class II41.8% (728) Class III50.3% (876) Class IV1.90% (33)Pulmonary hypertension6.0% (105) Mild2.9% (50) Moderate3.1% (54) Severe0.9% (15)Preoperative pacemaker4.5% (78)Preoperative acute kidney injury2.5% (44)Smoking (current or former)29.1% (507)Values are expressed as mean ± SD for continuous variables and as percentage (n) for categorical variables. BSA, Body surface area; euroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association. Table 1Baseline demographic and clinical characteristicsVariableValueAge, y73.2 ± 6.8Weight, kg75.1 ± 13.0Height, cm160.8 ± 9.1Body mass index, kg/m229.3 ± 11.1BSA, m21.79 ± 0.18Height/BSA index, cm/m290.5 ± 6.3euroSCORE II, %3.35 ± 4.5Male sex55.2% (962)Hypertension75.3% (1311)Diabetes mellitus Diet-controlled0.1% (2) Oral treatment4.8% (83) Insulin-treated2.0% (35)Dyslipidemia69.7% (1214)Atrial fibrillation10.7% (187)Chronic obstructive pulmonary disease11.4% (198)Severe peripheral arterial disease5.3% (92)Preoperative sinus rhythm58.7% (1023)NYHA functional class Class I0.75% (13) Class II41.8% (728) Class III50.3% (876) Class IV1.90% (33)Pulmonary hypertension6.0% (105) Mild2.9% (50) Moderate3.1% (54) Severe0.9% (15)Preoperative pacemaker4.5% (78)Preoperative acute kidney injury2.5% (44)Smoking (current or former)29.1% (507)Values are expressed as mean ± SD for continuous variables and as percentage (n) for categorical variables. BSA, Body surface area; euroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association. Baseline demographic and clinical characteristics Values are expressed as mean ± SD for continuous variables and as percentage (n) for categorical variables. BSA, Body surface area; euroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association. The mean age was 73.2 ± 6.8 years, and 55.2% of patients were male. The cohort was characterized by a high prevalence of cardiovascular risk factors, including hypertension, dyslipidemia, and obesity. Operative risk, as assessed by European System for Cardiac Operative Risk Evaluation II, was 3.35% ± 4.5%. Most patients were in New York Heart Association functional class II or III at the time of surgery, with a small proportion in class I (0.75%) and class IV (1.90%). Preoperative atrial fibrillation, chronic obstructive pulmonary disease, and peripheral vascular disease were present in a minority of cases. Procedural Characteristics Procedural characteristics are summarized in Table E1, Table E2, Table E3 and Figure 2. Isolated AVR accounted for the majority of cases (73.6%), whereas the remaining procedures involved combined cardiac surgery, most frequently concomitant coronary or mitral procedures.Figure 2Distribution of implanted prosthesis size. Distribution of implanted prosthesis size. Among patients undergoing isolated AVR, an upper J ministernotomy was the preferred surgical approach performed in 74.0% of cases (949), whereas a full sternotomy was used in 26.0% (333). Median aortic crossclamp and cardiopulmonary bypass times were shorter in isolated procedures compared with combined surgery and were lowest in isolated procedures performed through a ministernotomy approach. The distribution of implanted prosthesis sizes is shown in Figure 2, with medium (23 mm) and large (25 mm) valves being the most frequently implanted sizes. Permanent Pacemaker Implantation and Conduction Outcomes Overall, PPI due to complete atrioventricular block occurred in 96 of 1742 patients (5.5%). The cumulative incidence of PPI over the course of the program is shown in Figure 3. Early in the experience, cumulative PPI rates approached 12 to 14%, followed by a progressive decline and stabilization at approximately 5 to 6% after the first 500 cases.Figure 3Cumulative incidence of PPI over time. PPI, Permanent pacemaker implantation; AVR, aortic valve replacement. Cumulative incidence of PPI over time. PPI, Permanent pacemaker implantation; AVR, aortic valve replacement. When cumulative incidence was analyzed separately for the overall cohort and for isolated AVR, both curves demonstrated a parallel temporal evolution, with consistently slightly lower rates in isolated procedures (Figure 3). A clear inflection point was observed around case number 250, corresponding to the year 2017, after which the slope of cumulative PPI markedly decreased. The relationship between prosthesis size selection and patient body size was explored using heat-map analysis of PPI incidence according to prosthesis size and height/BSA index (Figure 4). Heat-map visualization was used as an exploratory, hypothesis-generating tool. The dashed line represents the cohort median of the height/BSA index. Before 2017, high PPI rates were observed across a broad range of prosthesis sizes and body size indices, including within intermediate ranges. After adoption of the standardized implantation strategy, PPI incidence became more uniformly distributed, with high-rate clusters largely confined to the extremes of the body size spectrum.Figure 4Heat-map: PPI versus prosthesis size and height/BSA index. PPI, Permanent pacemaker implantation; BSA, body surface area. Heat-map: PPI versus prosthesis size and height/BSA index. PPI, Permanent pacemaker implantation; BSA, body surface area. Univariable logistic regression analysis identified age as a significant predictor of postoperative PPI (odds ratio [OR], 1.06 per year; 95% CI, 1.02-1.10; P = .002). Combined surgery without concomitant coronary revascularization showed a borderline association with increased risk. Prosthesis size, body size indices, surgical approach, and year of surgery were not independently associated with PPI on univariable analysis. Variables considered clinically relevant or related to prosthesis sizing and surgical strategy were included in univariable analysis as shown in Table E3. In multivariable analysis, variables were selected based on clinical relevance and parsimony. Age remained an independent predictor of PPI (OR, 1.06; 95% CI, 1.03-1.10; P = .001), and combined noncoronary surgery was associated with increased risk (OR, 2.43; 95% CI, 1.35-4.39; P = .003). The standardized modified implantation strategy showed a nonsignificant trend toward reduced PPI (OR, 0.67; 95% CI, 0.39-1.13; P = .113). Model performance showed acceptable discrimination (area under the curve, 0.624). Results of the final model are summarized in Table 2 and Figure 5.Table 2Multivariable logistic regression analysis of factors associated with postoperative permanent pacemaker implantationVariableOdds ratio95% CIP valueAge (per year)1.061.03-1.10.001Combined noncoronary surgery2.431.35-4.39.003Combined coronary surgery0.790.43-1.45.441Endocarditis1.540.58-4.08.381Modified implantation technique0.670.39-1.13.113Model performance: LR χ2= 24.04 (P = .0002); pseudo-R2= 0.034; area under the curve = 0.624.Figure 5Multivariable predictors of postoperative PPI. Table 2Multivariable logistic regression analysis of factors associated with postoperative permanent pacemaker implantationVariableOdds ratio95% CIP valueAge (per year)1.061.03-1.10.001Combined noncoronary surgery2.431.35-4.39.003Combined coronary surgery0.790.43-1.45.441Endocarditis1.540.58-4.08.381Modified implantation technique0.670.39-1.13.113Model performance: LR χ2= 24.04 (P = .0002); pseudo-R2= 0.034; area under the curve = 0.624. Multivariable logistic regression analysis of factors associated with postoperative permanent pacemaker implantation Model performance: LR χ2= 24.04 (P = .0002); pseudo-R2= 0.034; area under the curve = 0.624. Multivariable predictors of postoperative PPI. Paravalvular leak was infrequent in the present cohort. At follow-up, moderate or severe paravalvular regurgitation was observed in 2.7% of patients, whereas the vast majority of cases were either absent or mild and without hemodynamic relevance. No increase in PVL was observed after implementation of the standardized implantation strategy. Discussion In this large single-center cohort, we evaluated postoperative PPI after sutureless AVR, focusing on the impact of a standardized anti-oversizing implantation strategy. The main finding is that technical refinement (specifically sizing interpretation and implant depth standardization) was temporally associated with a sustained decline in PPI over time; however, in adjusted analysis, the modified implantation strategy demonstrated only a nonsignificant trend toward reduced PPI. Although the cumulative incidence stabilized at approximately 5 to 6% in the later phase of the experience, the contemporaneous, noncumulative PPI rates after technique standardization consistently ranged between 3% and 4%. Beyond conventional descriptive analyses, this study introduces a novel graphical representation integrating prosthesis size and patient phenotype through a heat-map approach. This visualization allows identification of clusters of higher PPI incidence consistent with oversizing patterns, particularly evident in the early phase of the series. To our knowledge, this is among the first reports to depict oversizing as a measurable and reproducible phenomenon rather than a theoretical concept, generating a testable hypothesis linking prosthesis–annulus mismatch to conduction disturbances.17, 18, 19 A schematic representation of the modified implantation strategy is provided in Figure 1, highlighting the key technical principles aimed at minimizing conduction disturbances. Conduction disturbances after AVR are known to result from mechanical interaction between the prosthetic frame and the conduction system, particularly at the membranous septum and left ventricular outflow tract.6,18,19 In sutureless valves, the radial force exerted by the self-expanding nitinol frame, combined with implant depth, makes accurate sizing critical. Our heat-map analysis demonstrates that before 2017, higher PPI rates were not restricted to extreme anatomic phenotypes but extended into intermediate ranges of the height/BSA index, suggesting systematic oversizing rather than patient-driven risk alone.1,8,24 After implementation of the modified sizing strategy, high-risk zones became confined to phenotypic extremes, supporting the hypothesis that oversizing was effectively mitigated. These findings align with experimental and clinical observations indicating that even small increases in radial force or implant depth may significantly increase conduction injury. Of note, prosthesis size alone did not emerge as an independent predictor of PPI, reinforcing the concept that sizing must be interpreted in the context of patient anatomy rather than absolute valve diameter. Taken together, these findings suggest that conduction disturbances are more closely related to the mismatch between prosthesis size and patient anatomy than to absolute prosthesis size alone, supporting the concept of relative oversizing as a key determinant of conduction injury. The reduction in PPI observed after 2017 occurred without deterioration of procedural safety or operative efficiency. Clamp and cardiopulmonary bypass times remained low, particularly in isolated AVR performed via ministernotomy, supporting the reproducibility of the modified approach even in minimally invasive settings. In multivariable analysis, age and noncoronary combined surgery emerged as independent predictors of PPI, whereas the modified implantation strategy demonstrated only a nonsignificant trend toward reduced PPI. Although this effect did not reach conventional statistical significance, its clinical relevance is underscored by the temporal evolution of PPI rates and the convergence of incidence curves after technique standardization. Of note, combined noncoronary procedures were independently associated with increased PPI risk. This may reflect the close anatomic relationship between the conduction system and the central fibrous body, particularly in mitral-aortic surgery, where additional annular manipulation, traction, or septal edema may increase susceptibility to conduction injury. Further refinement of surgical techniques in this setting may help mitigate this risk. Taken together, these findings suggest that PPI after sutureless AVR may not be an unavoidable consequence of the technology, but rather a modifiable outcome dependent on procedural execution.6,20, 21, 22 The contemporary expansion of TAVR into younger and lower-risk populations has shifted the benchmark for procedural outcomes, particularly regarding conduction disturbances.25,26 Despite technical advances, PPI rates after TAVR remain consistently higher than those reported for surgical AVR, representing one of its main limitations in patients with long life expectancy.12,13 In this context, sutureless AVR occupies a strategic position, combining the hemodynamic and durability advantages of surgical valves with reduced operative times and minimally invasive access.17,27 However, to remain competitive, sutureless AVR must achieve conduction outcomes clearly superior to TAVR. Our data indicate that when oversizing is avoided through standardized sizing interpretation and implant depth control, PPI rates after sutureless AVR can be maintained at levels comparable to conventional surgical valves and substantially lower than those reported in contemporary TAVR series. This distinction is particularly relevant when treatment equipoise exists between transcatheter and surgical options. The findings of this study have direct implications for clinical practice. First, they emphasize that sizing should be interpreted dynamically rather than mechanically, particularly in arrested hearts where annular compliance may favor oversizing. Second, they support the routine adoption of standardized implantation strategies, especially in minimally invasive approaches where visual and spatial constraints may amplify technical variability. By actively avoiding oversizing, this approach targets key modifiable determinants of adverse outcomes associated with prostheses relying on radial force, notably conduction disturbances and paravalvular leak, 2 factors consistently linked to impaired long-term survival in contemporary valve replacement strategies, including transcatheter, sutureless, and rapid-deployment technologies. Finally, the heat-map representation proposed in this study offers a practical framework for quality control, training, and future comparative analyses across centers and technologies. The size and longitudinal consistency of the present cohort represent a major strength of this study. To date, this series constitutes the largest single-center experience with sutureless AVR using the Perceval prosthesis reported in the literature, allowing for a detailed assessment of temporal trends, technical refinement, and infrequent but clinically relevant outcomes such as PPI. The single-center design ensures procedural consistency and minimizes variability related to implant technique, thereby strengthening the interpretation of the observed associations.1,27 Limitations This study is limited by its single-center, observational design. Although the large sample size and longitudinal consistency strengthen internal validity, external generalizability may be influenced by center-specific expertise. Detailed intraoperative data regarding valve redeployment, embolization, or the need for repeat crossclamping were not systematically recorded and could not be analyzed. Preoperative conduction abnormalities, particularly right bundle branch block, are well-established predictors of postoperative PPI and were previously investigated in our institutional experience.21 In the present study, these variables were not systematically included due to incomplete availability across the entire study period and because the primary focus was on the impact of implantation strategy. Additionally, although the heat-map analysis provides strong visual and statistical support for the oversizing hypothesis, causality cannot be definitively established. Prospective validation in multicenter cohorts would be desirable. Detailed echocardiographic parameters and long-term durability outcomes were not analyzed in the present study and are the subject of a separate ongoing investigation. Conclusions Standardization of sizing interpretation and implant depth was associated with a sustained temporal decline in postoperative PPI, although the adjusted analysis showed only a nonsignificant trend toward reduction. Oversizing emerges as a modifiable and measurable driver of conduction disturbances. In the current era of expanding TAVR indications, optimizing sutureless AVR technique is essential to preserve its role as a competitive and durable surgical alternative. Webcast You can watch a Webcast of this AATS meeting presentation by going to: https://www.aats.org/resources/mitigating-conduction-disturba-12514. Declaration of Generative AI and AI-Assisted Technologies in the Writing Process During the preparation of this manuscript, the authors used OpenAI as a language-support tool to assist with the drafting and editing of the text. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Conflict of Interest Statement The authors reported no conflicts of interest. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.